SHANGHAI – For Xueming Qian, CEO and founder of Mabspace Co. Ltd., an antibody discovery engine based in Suzhou, the writing was on the wall. While pharma was de-emphasizing early stage research and putting it into the hands of biotechs in the U.S., the economy in China had hit an inflection point, the momentum was building. China was the place to be.